Treatment with either ETH1/2 extracts or pioglitazone successfully ameliorated INS resistance, hyperlipidemia, and fatty liver without significantly affecting fasting INS levels or pancreatic secretory capacity. It increased liver protection from injury associated with T2DM, as evidenced by a significant decrease in ALT and AST. This evidence concerns the gene GOT1 and hyperlipidemia.